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Abstract
Eosinophil infiltration is a common finding in a broad spectrum of skin diseases, despite the fact that the skin is devoid of
eosinophils under physiologic conditions. Although cutaneous eosinophilia is reactive, cytokine-mediated inmost cases, diseases
with an intrinsic mutation-mediated clonal expansion of eosinophils can also manifest on the skin. As eosinophils are involved in
host defense, regulate immune responses, generate pruritus, induce remodeling and fibrosis, and can cause tissue damage, they
have the capacity to actively contribute to the pathogenesis of diseases. Recent research provided deeper insights in the mech-
anisms, e.g., bacterial and viral clearance, blister formation, recruitment of cytotoxic T cells, and generation of pruritus, by which
eosinophils might come into action. This review aims at providing an overview on the clinical presentations of eosinophil-
associated dermatoses and the current understanding of their pathogenic role in these diseases. Further, we discuss the effects of
therapies targeting eosinophils.
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Introduction
Eosinophil infiltration of the skin is a frequent histopatho-
logical finding in a broad spectrum of dermatological disor-
ders. This observation might be astonishing considering the
fact that the skin does not harbor eosinophils under physio-
logic conditions. As eosinophilic dermatoses lack any spe-
cific clinical sign or pattern, a skin biopsy and histology
together with the clinical manifestations are often required
to get the correct diagnosis. Under the microscope, eosino-
phils easily attract attention as they appear as bright red
granular cells in hematoxylin and eosin (H&E) stained tis-
sue. Indeed, the affinity to the red dye eosin was the reason
why Paul Ehrlich named his newly discovered cells eosin-
ophils [1, 2]. Eosinophilic dermatoses present with or with-
out accompanying peripheral blood eosinophilia, defined as
absolute eosinophil counts >0.5 G/l [3]. The development of
targeted antieosinophil therapies that effectively deplete eo-
sinophils in the blood and tissues has tremendously accel-
erated research on eosinophils in order to understand their
function under physiologic and pathologic conditions. In
the field of dermatology, progress has been made in dem-
onstrating subgroups of eosinophils by their cytokine ex-
pression [4], different ways of mediator release [5],
eosinophil-mediated effects on blister formation in bullous
pemphigoid (BP) [6], vasopermeability [7], bacterial killing
[8], and pruritus [9, 10], in elucidating eosinophil activation
factors [8, 11], and roles in tumor biology [12, 13].
Moreover, antibodies affecting eosinophils have been dem-
onstrated to be effective in improving cutaneous manifesta-
tions of hypereosinophilic syndromes [14, 15].
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In this review, we are aiming at demonstrating the spectrum
of eosinophilic diseases affecting the skin with special focus
on the pathogenic roles of eosinophils and eosinophils as ther-
apeutic targets.
Eosinophils
As innate immune cells, eosinophils are involved in host de-
fense. They express several pattern recognition receptors, in-
cluding toll-like receptors (TLR), nucleotide-binding oligo-
merization domain-like receptors (NLRs), G protein-coupled,
Fc, chemokine, adhesion, and cytokine receptors [16, 17].
Receptor stimulation leads to degranulation of toxic granule
proteins (eosinophil peroxidase (EPO), eosinophil cationic
protein (ECP), eosinophil-derived neurotoxin (EDN), and ma-
jor basic protein (MBP)), synthesis of nitric oxide, release of
cytokines, and chemokines, and cell trafficking [16, 17].
Toxic granule proteins
Eosinophils are stuffed with granules, primary and secondary
ones. Primary granules harbor Charcot-Leyden crystal (CLC)
protein (galectin-10) and eosinophil peroxidase (EPO). A role
of CLC has been associated with various eosinophilic includ-
ing allergic and parasitic diseases. CLC is assumed to be in-
volved in vesicular transport of cationic RNases and the gran-
ule formation during eosinophil differentiation [18]. EPO has
been shown to exert antiparasitic and antibacterial effects. It is
released either into large cytoplasmic vacuoles (phagosomes)
or extracellularly where it binds to the surface of a target [18].
Secondary granules contain major basic protein (MBP) in
the crystalline core, as well as eosinophil cationic protein
(ECP), eosinophil-derived neurotoxin (EDN), and EPO in
their matrix. ECP was shown to directly damage
schistosomula of Schistosoma mansoni [19]. ECP, EDN and
MBP have antibacterial properties that are dependent or inde-
pendent of RNase activity [20–22]. Eosinophil-derived neu-
rotoxin (EDN) is a member of the RNase superfamily. In
addition to its ribonuclease activity resulting in neurotoxic
and antiviral effects, EDN serves as a chemoattractant of den-
dritic cells, and as an endogenous ligand for toll-like receptor
(TLR)2 [23]. ECP, MBP, and EPO have been identified as
major components of eosinophil extracellular traps (EET) [5,
24]. To note, in the process of EET formation, degranulation
and mitochondrial DNA release occur sequentially, suggest-
ing that the DNA scaffold and granule proteins associate in the
extracellular space [25]. In the granules, MBP is stored as
nanocrystals that are nontoxic [26]. Its toxicity is triggered
by granule acidification upon stimulation of eosinophils and
extracellular aggregation [26]. Interestingly, further aggrega-
tion of MBP results in large amyloid plaques that are nontoxic
and most likely limit tissue damage. Such MBP+ amyloid
plaques have been observed in biopsies from eosinophilic
cellulitis and atopic dermatitis (AD) [26].
Mediator release
Eosinophil function is dependent on the release of toxic gran-
ule proteins, cytokines, and chemokines (Fig. 1). These
mediators are mostly stored within the secondary granules of
eosinophils [27]. Different modes of degranulation exist,
determining the execution of eosinophil function. In
piecemeal degranulation, the most abundant form of
degranulation found in tissue sections, eosinophils are
capable of selectively secreting granule contents depending
on the stimulus. For example, stimulation of eosinophils
with RANTES or eotaxin-1 results in secretion of interleukin
(IL)-4, whereas upon interferon (INF)-γ stimulation, eosino-
phils secrete IL-12 but not IL-4 [28]. On an ultrastructural
level, piecemeal degranulation is characterized by a loss of
density of secondary granules and the presence of so-called
sombrero vesicles, corresponding to tubular structures serving
as secretory vesicles, finally fusing with the plasmamembrane
for mediator release [28]. Classical exocytosis has been ob-
served in close proximity to large parasites [29].
Eosinophil cytolysis, the second most common form of
granule protein release into tissues, is the result of utmost
activation of the eosinophil that results in cell death. On an
ultrastructural level, chromatolysis and loss of plasma mem-
brane integrity are found, alongside with deposits of so-called
clusters of free eosinophil granules (cfegs). Interestingly, these
partially intact cell-free granules appear to maintain effector
*
*
Fig. 1 Eosinophil infiltration in the skin. The image shows round shaped
eosinophils with their typical bi-lobed nuclei (arrow), cell-free granules
indicating degranulation (*), cytolytic eosinophils (arrowhead), and flame
figures presenting necrobiotic collagen fibres covered by eosinophil
granule proteins (open arrow). Magnification ×400
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function. Stimulation of cfegs with IL-4, RANTES or IFN-γ
resulted in stimulus-dependent mediator release [30, 31].
Recently, adhesion-induced cytolysis was characterized as a
nonapoptotic form of cell death with features of necroptosis,
counter-regulated by autophagy [32]. Cytolysis-associated
morphologic changes of eosinophils such as cytoplasmic
vacuolization have been observed in various dermatoses [32].
Catapult-like release of mitochondrial DNA that associates
with eosinophil granule proteins, resulting in the formation of
net-like structures, is referred to as EET formation [24].
Extracellular traps are formed by viable cells, therefore, cell
death, including eosinophil cytolysis, is not required [33].
Through EET formation, eosinophils are able to bind and kill
extracellular bacteria [8]. EETs have been detected in a variety
of skin disorders, including infectious, but also allergic and
autoimmune diseases [5, 34].
Cytokines expression by eosinophils
By the production and release of cytokines and chemokines,
eosinophils function as immunomodulatory cells. They are
often associated with type 2 inflammation as they respond to
IL-5 and secrete cytokine such as IL-4, IL-9, and IL-13 that
may affect Th2 cells, B cells, and macrophages [17]. By re-
leasing GM-CSF, IL-8, and IL-10, eosinophils have the po-
tential of attracting neutrophils, autostimulation, and immuno-
regulation [17]. Via synthesis of tumor necrosis factor
(TNF)-α, eosinophils may exert cytotoxic effects [35]. To
note, eosinophils are a source of IL-31, a cytokine that bridges
inflammation and pruritus [9]. There is evidence that, with
respect to cytokine production, distinct subpopulations of eo-
sinophils exist in the skin depending on the underlying disease
and inflammatory milieu [4].
Fibrosis
Eosinophils have been reported to express CCL11 (eotaxin-1),
tumor growth factor (TGF)-β, IL-6, IL-11, IL-13, andMMP-9
and thus may directly or indirectly stimulate tissue remodeling
or fibrosis. A correlation of tissue eosinophils and mediator
release with deposition of extracellular matrix proteins has
been shown in skin diseases [4], eosinophilic esophagitis
[36], and asthma [37]. TGF-β, which can either be released
by eosinophils or by epithelial cells upon stimulation with IL-
4 and IL-13, was shown to activate fibroblasts resulting in the
secretion of matrix proteins, as well as the release of eotaxin
stimulating an additional recruitment of eosinophils
[38].CCL11 has profibrogenic properties on fibroblasts ex-
pressing its receptor CCR-3 [39]. In mouse models, IL-11 that
is produced by eosinophils and structural cells, was shown to
stimulate fibrosis [40].
Potential roles of eosinophils in skin diseases
For most eosinophilic dermatoses, the exact pathogenic mech-
anism, specifically the role of eosinophils is still obscure.
Here, we will discuss some general mechanisms together with
the possible contribution of eosinophils.
Host defense
Eosinophils are assumed to be involved in killing helminths
particularly those in tissue-migratory stages by releasing toxic
granule proteins and reactive oxygen species, as well as me-
diating protection against reinfection [41]. Notably, released
eosinophil granule proteins cause concomitant tissue damage
contributing to the disease pathology [41]. Antibacterial ef-
fects by eosinophils have been attributed to toxic effects of
MBP and eosinophil cationic protein (ECP), the phagocytic
capacity of eosinophils, although this is much less compared
to neutrophils, and the formation of EETs [24]. Eosinophils
have also been shown to promote virus clearance by releasing
EDN, an RNase, that reduces virus infectivity, as well as ac-
tivates dendritic cells by interacting with TLR2 resulting in
IL-6 and TNF-α release, and functions as chemoattractant for
macrophages [42]. Furthermore, eosinophils may function as
antigen-presenting cells and stimulate CD8+ cells [43].
Edema and blister formation
Eosinophils may contribute to edema by releasing eosinophil
granule proteins, as well as by the production of leukotrienes
that have direct vasodilatory effects on blood vessels or indi-
rectly via stimulation of mast cells and basophils [44, 45].
Eosinophil infiltration in the skin and lining along the
dermal-epidermal junction are observed in bullous pemphi-
goid (BP), an autoimmune-bullous disease. In the presence
of BP autoantibodies eosinophils upon activation by IL-5
were shown to directly contribute to blister formation using
an ex vivo skin model [6]. Adhesion, Fcγ receptor activation,
elevated ROS production, and EET formation by eosinophils
have been shown to be involved in dermal-epidermal separa-
tion [6]. Furthermore, ECP and EDN have been reported to
exert cytotoxic effects on keratinocytes and cause cell-matrix
detachment [46].
Recruitment and activation of cytotoxic T cells
Through the recruitment and activation of cytotoxic T cells
and natural killer (NK) cells, eosinophils have been demon-
strated to restrict tumor growth [47–49], defend viral infection
[43], and, likely, are involved in drug rash with eosinophilia
and systemic symptoms (DRESS) [50].
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Induction of pruritus
Most eosinophilic dermatoses are associated with pruritus that
can be incredible, e.g., in atopic dermatitis, prurigo nodularis
and scabies. Eosinophils may stimulate nerve cells and con-
tribute to pruritus by releasing granule proteins (ECP, EDN,
MCP), mediators such as substance P, vasoactive intestinal
peptide, brain-derived neurotrophic factor, neurotrophin-3,
nerve growth factor, and cytokines such as IL-4, IL-13, and
IL-31 [51]. A key role of IL-31 in causing itch has been dem-
onstrated for atopic dermatitis, prurigo nodularis, dermatomy-
ositis, and, with a direct contribution of eosinophils, for BP
[10, 52–54]. In cutaneous T cell lymphoma (CTCL), eosino-
phil infiltration correlates with itch severity [55].
Primary and secondary causes of eosinophilia
Since the clinical presentation of eosinophilic dermatoses is
manifold and usually lacks specific criteria, a skin biopsy is
indispensable to establish the correct diagnosis by histologi-
cal, immunohistological and molecular analyses that should
be complemented by blood tests and, if required, imaging.
The accumulation of eosinophils in the skin and/or blood
and other organs can be caused by either a mutation or gene
fusion-mediated clonal expansion of eosinophils or a
cytokine-mediated increased differentiation and survival of
eosinophils. Intrinsic (clonal, neoplastic) eosinophilia is due
to genetic changes in hematopoietic stem cells leading to
chronic myeloid leukemias with eosinophils as part of the
clonally expanded cells. Extrinsic, reactive forms of eosino-
philia are the most common ones caused by cytokines such as
IL-3, IL-5, and GM-CSF that are released by mainly T cells,
as well as tumor cells [3, 56]. Determining the cause of eosin-
ophilia has immense implications on the therapy of the under-
lying disease [57–59].
Clinical patterns of eosinophilic dermatoses
Next, we will present the spectrum of eosinophilic dermatoses
based on their clinical presentations (Fig. 2) and provide cur-
rent knowledge on the pathogenesis with special focus on a
role of eosinophils.
Eczematous pattern
Atopic dermatitis is a common chronic inflammatory skin
disease with a prevalence of up to 20% in children and 8%
in adults [60]. It presents with highly pruritic eczematous skin
lesions affecting the face, neck, and extensor sites of the ex-
tremities in infants, as well as chronically inflamed lesions
with lichenification of the flexural folds in adults (Fig. 3A).
The pathogenesis is based on a genetic predisposition that
determines both skin barrier dysfunction and predominant
type 2 inflammation, as well as environmental factors [60].
Owing to the impaired skin barrier, the skin microbiome is
altered resulting in a colonization of Staphylococcus aureus
that further harm the barrier, the susceptibility to viral infec-
tion is increased, and environmental allergens may enter in the
skin. In consequence, innate and adaptive immune responses
are activated. Tissue eosinophilia that has been observed in
both acute and chronic AD lesions, is often accompanied by
elevated blood eosinophil levels correlating with disease se-
verity [61, 62]. In addition to intact eosinophils, cytolytic eo-
sinophils, extracellular granules, and eosinophil toxic protein
deposits have been found in AD skin [26, 61, 63, 64]. Thymic
stromal lymphopoietin (TSLP) that is highly expressed by
keratinocytes in AD was shown to stimulate EET formation
[8]. EETs were detectable in atopy patch test reactions as
model of an acute AD flare [5]. Eosinophils express type 2
cytokines and thus may actively contribute to AD inflamma-
tion. Pruritus can be stimulated by eosinophils as they release
toxic granule proteins, neuromediators, and cytokines, in par-
ticular IL-31 [51]. Blocking the IL-31 receptor results in a
rapid and significant reduction of pruritus followed by an im-
provement of AD severity [65]. As in allergic/reactive skin
diseases, eosinophils express IL-11, IL-13, TGF-β, and
CCL11, they would be able to induce fibrosis [4]. Thus, the
following roles of eosinophils in the pathogenesis of AD can
be hypothesized: defending invading pathogens by toxic gran-
ule proteins and EETs, stimulating inflammation, contributing
to fibrosis, and initiating pruritus. In patients with AD,
blocking IL-5 with mepolizumab had only slight effects on
disease severity [66, 67]. Althoughmepolizumab significantly
reduced blood eosinophils, it remains unclear whether it suf-
ficiently affected eosinophil infiltration and activation in
lesional AD skin.
Contact dermatitis, both allergic (ACD) and irritant (ICD),
presents with acute and/or chronic eczematous lesions trig-
gered by contact allergens and irritants, respectively.
Whereas in ICD the innate immune system is activated, in
ACD both innate and adaptive, mainly type 1, immune re-
sponses are involved. In both ICD and ACD, skin barrier
disruption followed by a proinflammatory cytokine milieu
and inflammation play an important pathogenic role [68].
Among skin infiltrating cells, few eosinophils are present.
Eosinophils generating EETs have been detected in ACD
[5]. Moreover, eosinophils that constitutively bear the lL-17
receptor together with Th17 cells are present in eczematous
skin lesions. The number of Th17 cells correlated with that of
MMP-9+ eosinophils, as well as tenascin deposition [69].
These observations suggest a role of eosinophils in pathogen
defense and in remodeling.
Worldwide, parasitic infections are the most frequent
causes of secondary eosinophilia. Scabies and larva migrans
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infection are common diseases. The skin infected by the sca-
bies mite Sarcoptes scabiei presents with papules and linear
burrows (Fig. 3A). It is infiltrated by mainly eosinophils, T
cells, monocytes, macrophages, and mast cells, resembling a
chronic allergic reaction [70]. Eosinophils have been demon-
strated to generate EETs and release toxic granule proteins in
both scabies and larva migrans skin lesions and thus would
have the capacity to contribute to clearing of pathogens [5].
Epithelial barrier defects and epidermal proliferation similar to
those in AD and psoriasis have been observed in scabies [70].
Eosinophils release cytokines and thus may stimulate adap-
tive, e.g., Th1, Th2, Th17, and regulatory T cells; immune
responses that can be either pro- or antiinflammatory [70]. It
is likely, that eosinophils contribute to bullous scabies
reported in several case reports [71]. Moreover, the intense
pruritus associated with scabies and larva migrans infection
might be promoted by eosinophils [10].
Epidermotropic forms of cutaneous T cell lymphoma
(CTCL) are characterized by the infiltration of malignant,
clonally expanded T cells [72]. The malignant cells resem-
ble central memory T cells in Sezary syndrome (SS), and
effector memory T cells in mycosis fungoides (MF) [73].
Erythroderma, severe pruritus, atypical T cells in the pe-
ripheral blood and lymphadenopathy are typical signs of
SS. MF presents with highly pruritic erythematous patches,
plaques, and tumors on the skin (Fig. 3A) [74]. MF and SS
have been associated with a Th 2 cytokine milieu including
elevated IL-5 expression leading to eosinophilia in skin
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and peripheral blood [75]. Interestingly, blood eosinophilia
was associated with disease progression and disease-
specific death [76].
Cutaneous manifestations are the most common organ
manifestations in patients with hypereosinophilia [77]. In
patients with hypereosinophilia due to T cells with an aberrant
immunophenotype, defined as lymphocytic variant of HES
(L-HES), a broad spectrum of pruritic skin lesions including
erythroderma, erythematous papules, urticarial plaques, and
poikiloderma can be observed [78, 79]. On histology,
A     Eczematous pattern
Atopic dermatitis Scabies
B     Macular and papular rash
Drug rash with eosinophilia and systemic symptoms 
Eosinophilic dermatitis (Wells syndrom)Urticaria
C     Urticarial pattern
D     Blisters and pustules
Bullous pemphigoid
Angiolymphoid hyperplasia with eosinophiliaGranuloma faciale
E     Nodular lesions
Cutaneous T cell lymphoma
Eosinophilic pustular folliculitis
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perivascular infiltrates with lymphocytes and eosinophils with
various degrees of epidermal involvement are evident [79].
The increased production of eosinophils and accumulation in
the skin is due to the production of IL-5 and/or IL-3 by aber-
rant T cells [78, 79]. Patients with L-HES and cutaneous in-
volvement respond usually well to anti-IL-5 and anti-IL-5
receptor therapy [14, 15].
Langerhans cell (LHC) histiocytosis may occur at any age
but primarily affects children. The skin lesions often present
with erythematous scaly or crusted papules and patches re-
sembling seborrheic eczema. In addition, pustules, vesicles,
petechiae, and purpura, as well as localized yellowish plaques
and macules, are observed [80]. The infiltrate in the papillary
dermis and epidermis harbors CD1a- and CD207-positive
LHC and numerus eosinophils [80]. Cytokines that may di-
rectly affect eosinophils, are produced by either LHC, e.g.,
GM-CSF, IL-10, IFN-γ, or T cells and macrophages, e.g.,
IL-3, IL-2, IL-4, IL-5, and TNF-α [81, 82].
Macular and papular rashes
Delayed-type drug hypersensitivity reactions (DDH) are con-
sidered to be mainly T cell mediated immune responses [83].
Eosinophils are commonly found both in the blood and, to a
smaller extent, in lesional skin of patients with DDH [84].
Despite this finding, surprisingly little is known about the
pathophysiological role of eosinophils in DDH.
Most DDH have a benign disease course such as
maculopapular drug eruptions [84]. Other, rare benign DDH
are the fixed drug eruption and the symmetrical drug-related
intertriginous and flexural exanthema (SDRIFE). Severe
DDH are rare, but potentially life-threatening. They include
acute general exanthematous pustulosis (AGEP), the hallmark
of which are nonfollicular pustules on an erythematous
ground and concurrent systemic involvement in about 20%
of cases [85], Stevens–Johnsons syndrome and toxic epider-
mal necrolysis that are characterized by epidermal detachment
and potential mucosal involvement, and drug rash with eosin-
ophilia and systemic symptoms (DRESS), an eosinophil-
predominated reaction [86].
DRESS, also known as drug-induced hypersensitivity syn-
drome, has an estimated incidence of 10 cases per million per
year [86]. The diagnosis of DRESS is based on a combination
of clinical symptoms and laboratory parameters (Table 1) [87,
88]. Cutaneous signs are rather nonspecific: a maculopapular
rash is the most common presentation, but urticarial lesions
and mucosal involvement have also been reported [86, 87, 89]
(Fig. 3B). Additional signs of DRESS include facial edema,
enlarged lymph nodes and fever, as well as positive serology
for viruses such as human herpes virus 6 (HHV6) and
Epstein–Barr virus (EBV) [90]. These features are paralleled
by a dysfunction of potentially any organ (Table 1). The liver
is most commonly affected (ca. 75% of the cases), followed
by kidneys and lungs (ca. 35%) [90, 91]. The mortality rate of
DRESS is 5–10% [92]. There is no pathognomonic histopa-
thology of DRESS, but interface dermatitis is the most com-
mon finding [50, 93]. While blood eosinophilia is a key fea-
ture of DRESS and present in the vast majority of patients,
cutaneous eosinophil infiltration and the presence of atypical
lymphocytes have been reported less frequently [50, 89].
In DRESS, T cells recognizing drug-derived haptens ex-
pand, a process that can be associated with reactivation of
certain viruses such as HHV6, herpes virus 1, EBV and cyto-
megalovirus [88]. IL-5 is considered the main driver of eosin-
ophil expansion and activation leading to organ damage and
dysfunction in DRESS [94]. The efficacy of antibodies
targeting the IL-5 / IL-5 receptor axis in severe DRESS are
an evidence for the key role of eosinophils in the pathogenesis
[95–97].
Urticarial pattern
In urticaria that presents with wheals, angioedema or both,
mast cells are the key drivers [98]. The acute form, clearing
within 6 weeks, is very common and mainly associated with
infections of the upper respiratory tract, drugs, and IgE-
Fig. 3 Clinical and histological presentations of dermatoses associated
with eosinophilia. Images demonstrate typical skin lesions and
pathological findings in H&E stained skin specimens of selected
dermatoses with eczematous pattern (A), macular and papular rashes
(B), urticarial pattern (C), blister and pustules (D), nodular lesions (E),
vasculitis (F), and fibrosis (G).
The key clinical and histopathological cutaneous features are the
following: (A) Atopic dermatitis: eczema in flexural folds, spongiosis,
acanthosis, superficial perivascular lymphohistiocytic infiltrate with
eosinophils; scabies: linear burrows, eosinophils are main infiltrating
cells; cutaneous T cell lymphoma: eczematous lesions, lymphocytic
infiltrate with epidermotropism, occasional eosinophils in dermis; (B)
DRESS: widespread erythematous macules and papules, facial edema,
unspecific histology, perivascular lymphohistiocytic infiltrate with
eosinophils; (C) urticaria: wheals, dermal edema and discrete mixed
infiltrate with few eosinophils; eosinophilic cellulitis/dermatitis:
urticarial patches; interstitial eosinophil infiltrate, flame figures; (D)
bullous pemphigoid: blisters in urticarial or eczematous lesions,
subepidermal blisters, numerous eosinophils in the dermis, lining at the
dermal–epidermal junction and in blisters; eosinophilic pustular
folliculitis: disseminated sterile pustules, intra- and perifollicular
eosinophil-rich infiltrate; (E) granuloma faciale: brownish-red nodules
and plaques; mixed, eosinophil-rich infiltrates with a grenz zone;
angiolymphoid hyperplasia with eosinophilia: grouped violaceous to
brownish papules and nodules, proliferation of blood vessels with
epitheloid endothelial cell proliferation with cytoplasmic vacuoles,
diffuse infiltrate of lymphocytes and numerous eosinophils; (F)
esinophilic granulomatosis and polyangiitis: purpuric nodules, intra-
and perivascular infiltrate of lymphocytes and eosinophils, destruction
of vessel wall, fibrinoid deposition; (G) eosinophilic fasciitis: plate-like
hardness of distal limbs, groove sign of blood vessels, thickening of
fascia, infiltrate of lymphocytes, plasma cells and eosinophils in early
stages
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mediated allergies. Physical stimuli such as heat, cold, vibra-
tion, and UV light are among the triggers of chronic inducible
urticaria. In a subgroup of patients with chronic spontaneous
urticaria (CSU), autoimmune responses have been identified
as relevant pathogenic mechanisms [98]. Eosinophils are
found among the mixed inflammatory infiltrate in the dermis
(Fig. 3C). Since eosinophils express tissue factor and VEGF,
as well as leukotrienes, they may increase vascular permeabil-
ity resulting in dermal edema and wheal formation [99–101].
A recent review pointed to eosinophil-mast cell interaction:
eosinophils may directly stimulate mast cells via the release of
toxic granule proteins provoking degranulation and stem cell
factor [101]. Interestingly, blood eosinopenia is associated
with higher disease activity and poor response to treatment
in CSU patients, in particular those with type IIb autoimmune
CSU [102].
Eosinophilic cellulitis/dermatitis (EC), also referred to as
Wells’ syndrome, is a rare dermatological condition charac-
terized by persistent urticarial plaques and sometimes blister
formation, as well as an eosinophil infiltrate in the dermis (Fig.
3C) [103]. Blood eosinophilia may be present. EC has been
considered an organ restricted eosinophilic disorder among
hypereosinophilic syndromes [104]. An increased expression
of IL-5 has been detected in both tissue and blood [105]. Both
eosinophils scattered throughout the dermis and extracellular
eosinophil granules have been observed [4, 5]. EET formation
is prominent and accentuated in eosinophil clusters, where up
to 50% of eosinophils generate EETs [5]. A typical, but not
pathognomonic finding is the presence of flame figures that
correspond to amorphous collagen fibers covered by eosino-
phil granule proteins suggesting a pathogenic role of toxic
granule proteins [5, 106]. Recently, an expression of CD25,
the alpha-chain of the IL-2 receptor, on blood and tissue eo-
sinophils of patients with EC that is mediated by high IL-5
expression, was demonstrated. Thus, IL-2 can act as potent
priming factor, resulting in a strong ECP release upon addi-
tional stimulation with platelet activating factor [11].
Recent data emphasize high effectiveness of mepolizumab,
an anti-IL-5-antibody, in the treatment of EC [107].
Episodic angioedema with eosinophilia (EAE), first de-
scribed by Gleich et al. 1984, is a rare episodic variant of
hypereosinophilic syndromes. It presents with recurrent at-
tacks of angioedema, urticaria, transient weight gain, fever,
and elevated leukocyte counts [108]. Abnormal CD3- CD4+
T cells have been detected in patients with EAE [109, 110].
Interestingly, a cycling of eosinophils together with other cell
lineages including neutrophils and lymphocytes has been ob-
served [109]. In addition to corticosteroids, mepolizumab and
imatinib have successfully been applied in patients with EAE
[111, 112].
Among specific dermatoses of pregnancy, polymorphic
eruption of pregnancy (PEP) and atopic eruption of
pregnancy (AEP) are the most frequent ones. They are asso-
ciated with intense pruritus [113]. Clinically, AEP patients
present with eczematous lesions and/or prurigo nodules
starting in the second or third trimester. PEP typically affects
primigravidae showing pruritic urticarial papules and plaques
[113]. The histopathological analysis of skin specimens re-
vealed the presence of eosinophils in 14/19 cases of AEP
and in all 22 cases of PEP [113].
Blisters and pustules
Bullous pemphigoid is the most common autoimmune bullous
skin disease affecting mainly the elderly. It is characterized by
an autoimmune response against hemidesmosomal antigens,
involving autoreactive T and B cells. BP presents with urti-
carial and eczematous lesions, as well as in general blisters.
Eosinophils infiltrating the skin are a striking histopathologi-
cal finding. They are located in the dermis, where they often
Table 1 Diagnostic criteria of
DRESS (RegiSCAR) [87] Criteria No Yes Unknown
Fever >38.5°C −1 0 −1
Lymphadenopathy 0 1 0






Resolution in >15 days −1 0 −1
Atypical lymphocytes 0 1 0
Blood eosinophilia
10–19.9% or 700–1499 Gpt/l
>20% or >1500 Gpt/l
0 1
2
Evaluation of other potential causes
(antinuclear antibodies, blood culture, hepatitis A, B, C serology,
chlamydia/mycoplasma)
0 1 0
*Heart, liver, kidney, muscle, pancreas or other
Scores 1–3: diagnosis uncertain; score 4 or higher: diagnosis certain
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line along the dermal-epidermal junction, and in blisters (Fig.
3D). Cytokines known to recruit and activate eosinophils such
as IL-5 and eotaxin are expressed in lesional skin [114, 115].
In the presence of BP antibodies, IL-5-activated eosinophils
have been demonstrated to cause splitting at the dermal-
epidermal junction in an ex vivo skin model [6]. BP is asso-
ciated with severe pruritus. Elevated IL-31 serum levels cor-
relating with numbers of eosinophil, which are a source of IL-
31, have been found in BP patients [10, 116]. In a clinical trial,
the anti-IL-5 antibody mepolizumab failed to significantly im-
prove BP [117]. The lack of efficacy could be explained by an
insufficient reduction of tissue eosinophils [117].
The pemphigus group is characterized by acantholysis of
keratinocytes due to antidesmoglein and antidesmocolin anti-
bodies resulting in blisters and erosions. Pemphigus vegetans
has been associated with eosinophil infiltration in the skin,
specifically eosinophil exocytosis and eosinophilic abscesses,
as well as elevated blood eosinophil and ECP levels [118].
However, the role of eosinophils in terms of epidermal disin-
tegration or hyperproliferation remains unclear.
Incontinentia pigmenti (IP) is caused by mutations of an X-
linked regulatory gene, termed nuclear factor-kappa B
(NF-κB) essential modulator (NEMO). The combination of
eosinophilic spongiosis, vesiculation, and dyskeratotic
keratinocytes is a distinct feature of IP [119]. In the initial,
vesiculo-bullous stage, the epidermis expresses eotaxin corre-
lating with the accumulation of eosinophils [120]. To note, the
eotaxin promoter has an NF-κB binding site [121].
Eosinophilic pustular folliculitis (EPF) is an inflammatory
skin conditions, typically presenting with sterile follicular
papulopustules (Fig. 3D). Three different subtypes have been
described so far, classical (Ofuji disease), immunodeficiency-
associated and EPF of infancy. The prompt therapeutic re-
sponse to indomethacin is pathognomonic. The histology
shows an accumulation of eosinophils in the pilosebaceous
unit. Recently, an increased expression of prostaglandin D
synthetase by inflammatory cells including eosinophils has
been demonstrated around the pilosebaceous unit [122].
Prostaglandin D2 induces mRNA expression of eotaxin-3
(CCL26), a potent chemoattractant for eosinophils, by human
sebocytes in a dose-dependent manner. These findings might
explain both the inflammatory pattern, as well as the therapeu-
tic effect of indomethacin [122]. In addition, increased expres-
sion of TNF-α by tissue eosinophils has been found in EPF
[4]. A pathogenic role of eosinophils is underlined by the fact
that the anti-IL-5 receptor antibody benralizumab is effective
in EPF [123].
Nodular lesions
Prurigo nodularis stands for a clinical reaction pattern in-
duced by chronic pruritus and permanent scratching present-
ing with symmetrically distributed, firm, hyperkeratotic,
excoriated nodules [124]. On histology, few eosinophils have
been detected in all specimens investigated, and extracellular
deposition of the eosinophil granule proteins were found in
most of them [125]. As eosinophils produce an armory of
toxic proteins, cytokines and mediators that can activate nerve
cells, they are predisposed to contribute to pruritus [126].
Solitary asymptomatic brown-red to livid papules, nodules
or plaques on the face are the typical clinical manifestation of
granuloma faciale (EF). Histologically, it is characterized by a
mixed cellular infiltrate, composed of lymphocytes, neutro-
phils, and eosinophils (Fig. 3E). An infiltrate-free grenz zone
in the papillary dermis is pathognomonic. Recently, a clonal
expansion of skin-homing CD4+ T cells has been demonstrat-
ed alongside with an increase in local IL-5 expression [127].
Increased IL-5 expression is associated with both increased
eosinophil recruitment, survival, and activation. The role of
the eosinophil itself in the pathogenesis of granuloma faciale
has not been determined yet. Recently, an EF sharing features
with an IgG4-associated sclerosing disease has been reported
[128].
Angiolymphoid hyperplasia with eosinophilia (ALHE) is a
benign vascular neoplasia with an eosinophil-rich infiltrate,
presenting as livid papule or plaque on the face. Kimura dis-
ease is defined by deep subcutaneous swellings, the presence
of blood eosinophilia, increased levels of total IgE alongside
with a lymphadenopathy [129]. Currently Kimura disease and
ALHE are considered as spectrum of the same disease. The
infiltrate is composed of T cells, B cells, eosinophils, and
plasma cells (Fig. 3E).
In ALHE lesions, eosinophils show a strong expression of
IL-13 and TGF-β , as well as CCL24 and MMP-9, pointing
toward a role of the eosinophil in immunoregulation and tissue
remodeling [4]. Mast cells and eosinophils in close proximity,
as well as T cells, can be found in Kimura disease [130]. As
mast cells and eosinophils produce IL-5, CCR3 and
RANTES, a bidirectional interaction of eosinophils und mast
cells can be assumed [130, 131].
Eosinophilic dermatosis of hematologic malignancy
(EDHM), previously also referred to as exaggerated insect
bite-like reaction, is mainly associated with chronic lymphatic
leukemia [132]. Clinically, it presents with pruritic papules
and occasionally bullae. Based on a clinical and immunohis-
tochemical study of six EDHM cases, Th 2 cells reactive to
malignant B cells by producing IL-5 have been suggested to
be responsible for eosinophil accumulation and activation,
and subsequent clinical signs and symptoms [133]. There is
evidence that neoplastic B cells are part of the infiltrate in
EDHM lesions [134].
Eosinophil infiltration is observed in various cutaneous
lymphomas. Primary cutaneous CD30+ T-cell lymphoprolifer-
ative disorders include lymphomatoid papulosis (LyP) and an-
aplastic large cell lymphoma (pcALCL) that manifest with pap-
ules, plaques, and nodules [135]. Patients with LyP that is self-
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healing, have an increased risk of developing secondary lym-
phoproliferative disorders such as a CD30+ ALCL, Hodgkin
lymphoma or mycosis fungoides [135]. The presence of eosin-
ophils in skin lesions is due to IL-3, IL-5, or GM-CSF expres-
sion by the malignant T cells [136]. In primary cutaneous B cell
lymphomas, an aberrant expression of the B cell lymphoma
(BCL)-6 transcriptional repressor protein regulating the tran-
scription factor GATA-3 is supposed to promote type 2 inflam-
mation and eosinophilia [137]. In Hodgkin lymphoma,
Hodgkin/Reed Sternberg tumor cells produce TNF-α that stim-
ulates eotaxin production by fibroblasts leading to eosinophil
recruitment [138]. Tissue eosinophilia has been associated with
poor prognosis [12]. Eosinophils secrete CD30 ligand that via
binding to CD30 on Hodgkin cells may promote tumor cell
proliferation and survival [12].
Opposite to the protumorigenic functions, eosinophils have
been reported to exert antitumorigenic activity. In melanoma
patients, the response to immune checkpoint inhibitor therapy
correlates with the increase of peripheral blood eosinophil
counts [13, 139]. Moreover, eosinophil activation and degran-
ulation of MBP, as well as an association of eosinophil and
CD8+ T cells numbers infiltrating the tumor tissue, have been
observed, suggesting both direct and indirect effects of eosin-
ophils in tumor defense [13].
Vasculitis
The diagnosis of eosinophilic granulomatosis with
polyangiitis (EGPA) is based on the occurrence of asthma
and other allergy symptoms, eosinophilia in blood and tissues
followed by eosinophilic granulomas and vasculitis that may
affect all organs including skin in the third phase (Fig. 3F)
[140]. As potential roles of eosinophils in EGPA pathogene-
sis, the production of cytokines such as IL-25 shaping Th2
inflammation, degranulation, toxic effects on tissues leading
to necrotizing granulomas, and destruction of small to
medium-sized vessel walls, as well as the release of tissue
factor and activation of platelets contributing to thromboem-
bolism, have been discussed [140]. Antibodies directed
against IL-5 or IL-5 receptor have been shown to be effective
in EGPA [141–143].
Fibrosis
Eosinophilic fasciitis (EF) often starts with an edematous
phase followed by a bilateral, symmetrical solid hardening
of the skin on the limbs why it has been considered a subtype
of scleroderma (Fig. 3G) [144]. Blood and tissue eosinophilia
occur during the early stages. In addition, a thickened fascia,
Table 2 Antieosinophil targeted therapies
Target Name Effect on eosinophils Effective in






Reslizumab Chronic spontaneous urticaria, cold urticaria [149]
EGPA [143]




Eotaxin-1 Bertilimumab Recruitment BP Phase 2a Study (NCT02226146), results not available
Siglec-8 Antolimab Depletion
+ reduction of mast cell activation
Chronic spontaneous urticaria [101, 150]
IL-4/IL-13Rα Dupilumab Activation









Janus kinase Tofacitinib Ruxolitinib Blocking JAK and STAT3
+ decrease type 2 inflammation




AD, atopic dermatitis; BP, bullous pemphigoid; DRESS, drug rush with eosinophilia and systemic symptoms; EDHM, eosinophilic dermatosis of
hematologic malignancy; EGPA, eosinophilic granulomatosis and polyangiitis; EPF, eosinophilic pustular folliculitis; HES, hypereosinophilic
syndrome
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as well as an inflammatory infiltrate of lymphocytes and plas-
ma cells, occasionally a fibrosis of the dermis can be observed
on histology [144]. In patients with EF, elevated IL-5 and ECP
levels have been detected [144, 145]. As eosinophils are
known to stimulate fibrosis via the release of toxic granule
proteins, metalloproteinases, and TGF-β, they are assumed
to contribute to the pathogenesis of EF.
Eosinophils are part of the cutaneous inflammatory infil-
trate in systemic sclerosis and localized scleroderma [146].
For the latter, an endothelial injury followed by the recruit-
ment of eosinophils, T cells, and macrophages, as well as
the secretion of fibrogenic cytokines including IL-4, IL-6,
and TGF-β, have been considered as important pathogenic
factors [146].
Targeting eosinophils as therapeutic
approach
Over the last decade with the development of targeted thera-
pies, eosinophils have caught attention as treatment targets.
Antibodies blocking IL-5 and IL-5 receptor have been ap-
proved for asthma and have successfully been tested in
hypereosinophilic syndromes. An increasing number of case
reports and case series demonstrate the efficacy of
mepolizumab, reslizumab, and benralizumab in various eosin-
ophilic dermatoses (Table 2). By reducing type 2 inflamma-
tion and thus impacting eosinophil responses, drugs such as
dupilumab are effective in many diseases beyond AD
Conclusion
Eosinophil infiltration in the skin is a frequent finding in a
broad spectrum of dermatoses and often an indicative finding
for the diagnosis. However, the exact roles of eosinophils need
to be defined in most of these diseases. The use of novel
targeted therapies and monitoring their effects on clinical
signs and symptoms, as well as the numbers and functions
of eosinophils including their interactions with tissue specific
and inflammatory cells, provide an opportunity to better de-
fine the pathogenic role of eosinophils.
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